Twenty-seven-year-old Illumina, Inc, one of the early genetic biotechnology companies and sequencing giant, has filed a lawsuit against Element Bioscience, a company founded by Illumina former employees, claiming patent infringement.
At stake, apparently, is a gene sequencing system which has implications for the nascent by very exciting new field of orthogenomics. Orthogenomics (aka: OG?) is the study of those genetic elements that may underly such chronic diseases as osteoarthritis, regenerative repair of musculoskeletal injury and inflammation in general. Could orthogenomics eventually yield a new generation of diagnostic and treatment tools, if not algorithms, for orthopedics and spine? Likely, yes.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
